Calcineurin inhibitors and the generalization of the presenting protein strategy

Advances in Protein Chemistry

Volumn 56, Issue , 2001, Pages 253-291

  Vogel, Kurt W ^a   Briesewitz, Roger ^a   Wandless, Thomas J ^b   Crabtree, Gerald R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Maxygen   (United States)

^d Present address: Advanced Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABIN 1; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLOPHILIN; CYCLOSPORIN A; CYTOPLASM PROTEIN; FK 506 BINDING PROTEIN; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; MEMBRANE ENZYME; MEMBRANE PROTEIN; NUCLEAR FACTOR OF ACTIVATED T CELL; NUCLEAR PROTEIN; PROTEIN BCL 2; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BINDING AFFINITY; CALCIUM TRANSPORT; CYTOKINE RELEASE; DRUG CONFORMATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME LOCALIZATION; HEART DEVELOPMENT; HEART HYPERTROPHY; HUMAN; IMMUNE SYSTEM; NERVE CELL PLASTICITY; NERVE REGENERATION; NERVOUS SYSTEM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0035064031     PISSN: 00653233     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0065-3233(01)56008-8     Document Type: Review

References (120)

1. Selective inhibition of NF-AT activation by a peptide spanning the calcineurin targeting site of NF-AT
2. Structural plasticity in a remodeled protein-protein interface
3. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction
4. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3
5. Cyclosporin A, an inhibitor of calcineurin, impairs memory formation in day-old chicks
6. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
7. Probing immunosuppressant action with a nonnatural immunophilin ligand
8. 2+- and stimulus duration-dependent switch for hippocampal gene expression
9. Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces
10. Stabilization of calcium release channel (ryanodine receptor) function by FKS06-binding protein
11. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FKS06-like domain
12. 2+ flux
13. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux
14. Characterization of calcineurin in human neutrophils. Inhibitory effect of hydrogen peroxide on its enzyme activity and on NF-KB DNA binding
15. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP
16. Identification of calcineurin as a key signalling enzyme in T cell activation
17. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein
18. Sequence-analysis of the ryanodine receptor: Possible association with a 12KD, FK506-binding immunophilin protein-kinase-C inhibitor
19. Contingent genetic regulatory events in T lymphocyte activation
20. 2+, calcineurin, and NF-AT
21. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution
22. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum
23. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin
24. The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin
25. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
26. Specific inhibition of calcineurin by type II synthetic pyrethroid insecticides
27. Pyrethroid insecticides as phosphatase inhibitors
28. On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin
29. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins
30. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
31. Characterization of a mutant calcineurin A α gene expressed by EL-4 lymphoma cells
32. Peptidylproline cis-trans-isomerases: Immunophilins
33. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen
34. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506
35. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve
36. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral-nerve injury
37. X-ray structure of calcineurin inhibited by the immnnophilin-immnnosuppressant FKBP12-FK506 complex
38. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice
39. FKBP12-binding domain analogs of FKS06 are potent, nonimmunosuppressive neurotropic agents in-vitro and promote recovery in a mouse model of Parkinsons' disease
40. Immunophilins: Beyond immunosuppression
41. Cyclophilin: A specific cytosolic binding protein for cyclosporin A
42. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase
43. Identification of an autoinhibitory domain in calcineurin
44. Incidence of congenital heart disease: II. Prenatal incidence
45. Cydosporine induces cancer progression by a cell-autonomous mechanism
46. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12
47. Functional domain structure of calcineurin A: Mapping by limited proteolysis
48. FK506 binding protein associated with the calcium release channel (ryanodine receptor)
49. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes
50. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases
51. Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A
52. Regulation of new DNA synthesis in mammalian cells by cyclosporine. Demonstration of a transforming growth factor beta-dependent mechanism of inhibition of cell growth
53. FK-506, A novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics
54. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex
55. Calcineurin: A calcium- and calmodulin-binding protein of the nervous system
56. Cain, a novel physiologic protein inhibitor of calcineurin
57. Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: Demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction
58. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution
59. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
60. Calcineurin binds the transcription factor NF-AT1 and reversibly regulates its activity
61. 2+/calmodulin-dependent phosphatase inhibitor, inhibits the induction of long-term potentiation in the rat hippocampus
62. Calcineurin inhibitors, FK506 and cyclosporin A, suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus
63. Calcineurin inhibitors and cardiac hypertrophy
64. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia
65. Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory
66. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study
67. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes
68. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure
69. Calcineurin inhibition and cardiac hypertrophy (in Technical Comments)
70. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
71. GATA4: A novel transcriptional regulator of cardiac hypertrophy?
72. Results of Renal Transplantation
73. The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity
74. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression
75. Calcineurin inhibition and cardiac hypertrophy (in Technical Comments)
76. NF-AT components define a family of transcription factors targeted in T-cell activation
77. Prevention of cardiac hypertrophy by calcineurin inhibition: Hope or hype?
78. Regulation of calcineurin phosphatase activity and interaction with the FK-506• FK506 binding protein complex
79. X-Ray structure of a decameric cyclophilin-cyclosporin crystal complex
80. The transcription, factor NF-ATc is essential for cardiac valve formation
81. Transcription factors of the NF-AT family: Regulation and function
82. Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons
83. Cyclosporin-A, a peptide metabolite from Trichoderma polysporum rifai, with a remarkable immunosuppressive activity
84. Competitive inhibition of calcineurin phosphatase activity by its autoinhibitory domain
85. Chemistry and biology of the immunophilins and their immunosuppressive ligands
86. Immunophilins, ligands, and the control of signal transduction
87. Identification of a putative regulator of early T cell activation genes
88. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2
89. 2+-activated cell death in mammalian cells
90. Role of kinases the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4
91. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12
92. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin
93. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?
94. Gene targeting and the biology of learning and memory
95. Immunophilins in the nervous system
96. Neural actions of immunophilin ligands
97. Synthesis and Analysis of 506BD, a high-affinity ligand for the immunophilin FKBP
98. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A
99. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models
100. A million dollar question: Does LTP = memory?
101. Calcineurin-immunosuppressor complexes
102. Signaling in myocardial hypertrophy: Life after calcineurin?
103. Cabin 1, anegative regulator for calcineurin signaling in T lymphocytes
104. Prevention of cardiac hypertrophy in mice by calcineurin inhibition
105. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin
106. Structure of FK506: A novel immunosuppressant isolated from Streptomyces
107. 2+ signals and immunosuppression
108. An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex
109. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex
110. Atomic structure of the rapamycin human immunophilin FKBP-12 complex
111. Tacrolimus (FK 506) in kidney transplantation
112. Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: Requiescat in pace?
113. 2+ signaling mechanisms in hippocampal CA1 neurons
114. Superoxide dismutase protects calcineurin from inactivation
115. Signal transduction by lymphocyte antigen receptors Cell
116. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NF-ATp)
117. Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin
118. Calcineurin regulation of synaptic function: From ion channels to transmitter release and gene transcription
119. NF-AT activation requires suppression of Crml-dependent export by calcineurin
120. A selective role of calcineurin A-α in synaptic depotendation in hippocampus